Novosibirsk · Russian-qualified counsel Recognised by Pravo-300 · Best Lawyers · Kommersant
Business Crime Defence

Corporate liability under Russian criminal law in the pharmaceuticals sector: key developments in 2027

Vitaliy Vetrov · June 2026 · 10 min read

Russian pharma executives face expanded criminal exposure under amendments effective January 2027. What foreign managers need to know. Make an enquiry.

Amendments to the Russian criminal framework governing the pharmaceuticals sector, which came into force in January 2027, have materially widened the exposure of company officers — including foreign nationals serving in managerial roles — to criminal liability in Russia. The changes extend the scope of offences that may be attributed to individuals holding formal or de facto authority within pharmaceutical companies, tighten the standards applied to product registration and distribution authorisation, and introduce revised presumptions about personal culpability when regulatory violations are identified. For foreign executives managing Russian pharmaceutical operations, understanding the new landscape is a practical priority, not an abstract compliance exercise.

§ I. What has changed in Russian pharmaceutical criminal law?

The January 2027 amendments build on a trajectory that Russian legislative bodies have pursued for several years: progressively converting administrative and regulatory non-compliance in the pharmaceuticals sector into conduct that may attract criminal, rather than merely civil or administrative, consequences. Three areas of substantive change are particularly significant for foreign managers.

First, the amendments have revised the thresholds at which violations of pharmaceutical product authorisation and registration rules cross from administrative into criminal territory. Previously, criminal liability in this area generally required evidence of large-scale harm or a deliberate falsification of documentation. Under the revised framework, the threshold for criminal proceedings has been lowered: conduct that causes or risks causing harm — including in circumstances where a responsible officer knew, or should have known, of a registration deficiency — may now be sufficient to initiate a criminal inquiry. This is a meaningful shift for any officer who holds nominal responsibility for regulatory compliance within a company's Russian operations.

Second, the amendments address the position of individuals who do not formally hold the title of director or general manager but who exercise substantive decision-making authority over pharmaceutical supply chain and product management decisions. Russian criminal procedure has, for some years, permitted the attribution of liability to de facto managers — those whose instructions governed the company's conduct regardless of their formal designation. The 2027 amendments have reinforced and, in certain respects, codified this approach, reducing the scope for an executive to argue that liability rests with a Russian national colleague who held the formal title.

Third, the amendments introduce revised standards for documenting the provenance and authorisation status of pharmaceutical products at each point in the supply and distribution chain. Failures in chain-of-custody documentation — even where the underlying product is genuine and properly authorised — may now trigger separate criminal exposure for the officers responsible for compliance systems. For foreign pharmaceutical companies operating through Russian subsidiaries or representative offices, this places renewed emphasis on the adequacy of internal controls, not merely on the licensing status of the product itself.

"[The 2027 amendments do not create entirely new categories of crime — they lower the threshold at which existing offences attach to officers whose companies breach pharmaceutical regulatory rules, and that distinction matters enormously for how a defence is framed.]" — Vitaliy Vetrov, Managing Partner, Vetrov & Partners

§ II. Which foreign executives are most directly affected?

The practical scope of the January 2027 changes is not limited to executives who are physically present in Russia or who hold Russian residency. The Russian criminal framework, as developed through court practice over the past decade, applies to individuals who exercise authority over Russian legal entities or their operations — and this test can be met by an executive based outside Russia who issues instructions, approves budgets, or authorises product and compliance decisions affecting the Russian subsidiary.

For foreign nationals in senior roles at Russian pharmaceutical companies, the principal areas of exposure under the revised framework are as follows.

Executives formally designated as general director, chief executive, or operations director of a Russian pharmaceutical entity bear the most direct exposure. Their authority over product registration, supply chain decisions, and internal compliance systems is presumed under Russian corporate law, and the January 2027 amendments reinforce the connection between that presumed authority and personal criminal accountability when regulatory violations are identified.

Regional directors or country managers for pharmaceutical multinationals who are employed by a foreign parent company but who exercise operational direction over the Russian entity — including approving distribution arrangements, signing off on regulatory submissions, or overseeing product safety monitoring — may fall within the de facto manager category that the 2027 amendments have codified. The determination is fact-specific and will depend on the documentary and communications record of how decisions were actually made.

Compliance and regulatory affairs officers, whether Russian nationals or foreign executives, who have formal or practical responsibility for the company's pharmaceutical registration and distribution authorisation portfolio face exposure specifically in relation to the new chain-of-custody documentation requirements. An officer whose written remit includes oversight of that documentation — or who is identified in internal records as the responsible person — is, under the revised framework, a potential subject of inquiry when deficiencies are found.

For in-house counsel and external advisers supporting pharmaceutical companies with Russian operations, the implications of these changes extend to how authority and responsibility are documented in corporate governance instruments — including powers of attorney, internal approval policies, and the terms of management agreements between parent companies and Russian subsidiaries.

If you hold a management, compliance, or directorial role at a Russian pharmaceutical company and are concerned about your personal exposure under the January 2027 amendments — discuss your situation in confidence: info@vetrovpartners.com |

§ III. What should foreign managers do now?

The appropriate response to the January 2027 changes is a structured review of personal and corporate exposure — not a wholesale change to business arrangements, but a considered assessment of where the gaps lie and what they mean in practice.

The starting point is a review of formal authority. Foreign executives should, in consultation with qualified Russian criminal defence counsel, examine how their authority over the Russian entity is documented — formally and informally. Powers of attorney, management agreements, board and shareholder resolutions, and the company's internal authorisation policies all contribute to a picture of who holds accountable authority for pharmaceutical regulatory compliance. Where that picture is unclear or where authority is unduly concentrated in a foreign executive without adequate Russian management involvement, restructuring the governance arrangements is worth considering.

The second step is a review of documentation systems for product registration and supply chain compliance. The new chain-of-custody provisions require companies to demonstrate, through contemporaneous records, the authorisation status of pharmaceutical products at each stage of distribution. Companies whose documentation practices were adequate under the pre-2027 framework should not assume that adequacy continues under the revised standards. An internal audit of compliance documentation — ideally conducted under legal professional privilege — provides both a diagnostic tool and, if a criminal inquiry were ever initiated, a potential line of defence.

The third step is to ensure that any existing reporting or escalation protocols for regulatory non-compliance are fit for purpose under the revised framework. One consistent feature of Russian criminal investigations in the pharmaceutical sector is the significance attached to what a responsible officer knew and when. Internal procedures that record the identification of compliance issues, the steps taken to resolve them, and the officers involved in that process create a contemporaneous evidential record that can be material in any subsequent proceedings.

Foreign executives who have not previously sought Russian criminal defence counsel for a pharmaceutical sector matter should treat the January 2027 amendments as a prompt to establish that relationship — not because prosecution is imminent, but because the forensic and procedural complexity of the Russian criminal process makes early preparation significantly more effective than reactive instruction.

The firm's Business Crime Defence practice advises foreign executives on personal criminal exposure in Russia, including in the pharmaceuticals, extractives, and financial services sectors. Related analysis on corporate liability in Russian criminal proceedings is available in The law and practice of corporate liability under Russian criminal law and Foreign creditors and corporate liability under Russian criminal law. The firm's Matters page contains further examples of relevant matters handled.

§ IV. Open questions – pending interpretation and regulatory guidance

The January 2027 amendments have introduced a number of provisions whose precise application will depend on how Russian investigative bodies, prosecutors, and courts interpret the new statutory language in the months ahead. Several areas remain genuinely uncertain at the point of publication.

The scope of the de facto manager provisions — which the amendments have codified rather than created — is likely to generate significant litigation as prosecutors seek to apply the revised framework to executives whose formal titles do not reflect their actual authority. The boundaries of that category are not fully resolved in the existing case law, and the 2027 amendments have not provided a definitive statutory definition. Courts in different circuits may reach different conclusions on fact-specific questions about what level of operational involvement is sufficient.

The threshold between administrative and criminal liability for registration and authorisation violations — lowered by the amendments — will also require judicial elaboration. Russian pharmaceutical regulation is sufficiently technical that the line between a negligent compliance failure and the kind of knowing or reckless conduct that attracts criminal liability is not always obvious from the face of the statute. Guidance from the Supreme Court or from the General Prosecutor's office, if it materialises, will be significant.

Finally, the interaction between the revised Russian framework and the regulatory obligations imposed on pharmaceutical companies by EAEU-level regulation — which governs the recognition and validity of product authorisations across Russia and other EAEU member states — has not been addressed by the January 2027 amendments. It is not yet clear how Russian courts will treat an EAEU-compliant authorisation in the context of a Russian domestic criminal proceeding relating to chain-of-custody documentation.

The firm will publish updates as regulatory guidance and early case law clarify these points. Foreign executives who require advice in the interim should not wait for that clarity before reviewing their own position.

Frequently asked questions

Q: What specifically changed in Russian criminal law affecting the pharmaceuticals sector in January 2027?

A: The January 2027 amendments made three substantive changes relevant to pharmaceutical sector executives. They lowered the threshold at which regulatory violations in product authorisation and registration can attract criminal, rather than merely administrative, consequences. They reinforced and codified the existing de facto manager doctrine, which allows criminal liability to attach to individuals who exercise real decision-making authority regardless of their formal corporate title. And they introduced new documentation requirements for pharmaceutical supply chain and chain-of-custody compliance, creating separate criminal exposure for officers responsible for those systems when deficiencies are identified. The overall effect is to widen the realistic scope of personal criminal liability for those managing Russian pharmaceutical operations.

Q: Which foreign executives and companies are most directly affected by the 2027 amendments?

A: The amendments most directly affect foreign nationals holding general director, operations director, or country manager roles in Russian pharmaceutical entities — and, more broadly, any foreign executive who can be shown to have exercised substantive authority over the Russian entity's regulatory compliance, product management, or distribution decisions, regardless of their formal title or the country from which they operate. Foreign pharmaceutical companies operating through Russian subsidiaries or representative offices are affected institutionally, but it is the individuals with documented or demonstrable authority who face personal criminal exposure. The revised de facto manager provisions mean that physical presence in Russia or a Russian-law employment contract is not a prerequisite for exposure.

Q: What should a foreign executive do if they are concerned about their position under the January 2027 amendments?

A: The immediate practical step is to seek advice from qualified Russian criminal defence counsel — before any inquiry is initiated, not after. A structured review of how authority is documented within the Russian entity, whether compliance documentation for pharmaceutical registration and supply chain requirements is adequate under the revised standards, and whether internal reporting protocols are fit for purpose under the new framework can be completed in a matter of weeks. That review provides both a diagnostic assessment of current exposure and, if a criminal inquiry were subsequently initiated, a documented basis for a defence. Early instruction is materially more effective than reactive engagement after an investigation begins.

Practitioner note

This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.

Facing a matter like this?

Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.

Make an enquiry